The NEU3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B-cell line, with disruption of the NEU3 gene to create a loss-of-function model. This polyclonal population avoids bottlenecks of clonal isolation and maintains a consistent knockout phenotype, offering robust and reproducible NEU3-deficient cells for glycobiology and lymphoma studies.
The Raji host cell line is a human Burkitt lymphoma model that is Epstein-Barr virus (EBV)-positive and expresses B-lymphocyte markers CD19 and CD20. These suspension lymphoblastoid cells are widely employed in immunology and cancer research, particularly for investigating lymphomagenesis, viral oncogenesis, and antibody-based therapies. The well-characterized nature of Raji facilitates seamless integration of the NEU3 knockout into existing experimental frameworks for drug screening and signaling dissection.
NEU3 encodes a plasma membrane sialidase that hydrolyzes sialic acid residues from gangliosides, notably GM3, GD3, and GM1, thereby altering lipid raft composition and cell surface glycosylation. NEU3 expression is regulated by the transcription factors SP1 and AP-1 downstream of cytokines and phorbol esters. At the membrane, NEU3 interacts with caveolin-1 and Grb2 within rafts to modulate epidermal growth factor receptor (EGFR) signaling and integrin-mediated adhesion. This activity promotes ceramide generation, which can activate caspase-3-dependent apoptosis. Through these mechanisms, NEU3 integrates glycosphingolipid metabolism with critical decisions in proliferation and survival.
In Raji lymphoma cells, dysregulated NEU3 may enhance prosurvival EGFR signals and alter ganglioside profiles, contributing to immune evasion and apoptosis resistance. The polyclonal knockout model enables clean dissection of NEU3??s contributions to these processes without residual enzyme activity, allowing direct assessment of changes in glycolipid composition, cell adhesion properties, and apoptotic thresholds. Researchers can also explore the interplay between EBV-driven latency programs and host sialylation, providing insights into glycosylation-dependent mechanisms of lymphoma progression and drug response.
Research applications of these knockout cells encompass cancer glycobiology, signal transduction studies, drug resistance mechanisms, apoptosis research, and immunotherapy strategies targeting sialylation. Representative experimental approaches include western blotting for NEU3, sialidase activity assays, ganglioside analysis by thin-layer chromatography or mass spectrometry, and flow cytometry for cell surface sialylation. Downstream analyses can involve EGFR phosphorylation assessment and ceramide quantitation, while cellular phenotypic assays such as Annexin V staining, adhesion assays, and MTT or BrdU proliferation tests provide comprehensive functional readouts. Together, these tools support detailed characterization of NEU3 function in B-cell malignancies. For more information, please contact Ascent Research.
